The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This study sought to investigate the efficacy and safety of a three-drug combination
antiemetic regimen of olanzapine combined with aprepitant and palonosetron for the prevention
of chemoradiotherapy-induced nausea and vomiting in locally advanced head and neck squamous
cell carcinoma.